Dexcom (DXCM) Cash from Financing Activities (2010 - 2026)

Dexcom (DXCM) has reported Cash from Financing Activities for 17 consecutive years, with -$607.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 35623.53% year-over-year to -$607.3 million in Q2 2026; TTM through Jun 2026 was -$2.3 billion, a 220.29% decrease from a year earlier, with the FY2025 full-year figure at -$1.7 billion, down 129.5% from the prior year.
• Cash from Financing Activities was -$607.3 million for Q2 2026 at Dexcom, down from -$25.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $939.5 million in Q2 2023 and troughed at -$1.5 billion in Q4 2025.
• A 5-year average of -$218.0 million and a median of -$3.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 21948.84% in 2023 and tumbled 95037.5% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$1.0 million in 2022, then plunged by 63090.0% to -$631.9 million in 2023, then surged by 99.75% to -$1.6 million in 2024, then plunged by 95037.5% to -$1.5 billion in 2025, then surged by 60.1% to -$607.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$607.3 million (Q2 2026), -$25.0 million (Q1 2026), and -$1.5 billion (Q4 2025), per Business Quant data.